Please ensure Javascript is enabled for purposes of website accessibility

Is BioCryst Pharmaceuticals Stock a Buy?

By Mark Prvulovic - Updated Aug 3, 2020 at 4:05PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Forget its coronavirus treatment, berotralstat could be BioCryst's next blockbuster drug.

There are plenty of companies now developing treatments against the coronavirus to try to contain the pandemic. Small-cap biotech BioCryst Pharmaceuticals (BCRX -0.63%) is among them, and its COVID-19 drug is currently in early stage clinical testing.

While most companies working on a COVID-19 treatment have seen their shares jump, BioCryst has been a surprising underperformer so far this year. Its stock is up 19.7% since the start of the year, slightly ahead of the Nasdaq's 18.1% gain during the same period. In comparison to some of the other hot coronavirus stocks on the market, however, this performance really isn't that great.

What does this mean for investors? Is BioCryst a potential diamond in the rough, or is the company really just not that remarkable after all? Let's see what else this company has to offer, and whether it deserves a spot in your portfolio.

Scientist holding a vial that's labelled "coronavirus."

Image source: Getty Images.

What BioCryst brings to the table

There are different types of treatments targeting COVID-19, with some of the most popular being vaccines. Gilead's remdesivir was one of the very first antiviral treatments to be tested on COVID-19 patients earlier this year.

BioCryst is working on its own antiviral drug, galidesivir, which has shown positive results in its early phase 1 trial and has now begun a phase 2 trial in Brazil. Just like remdesivir, which was originally designed to treat Ebola, galidesivir was originally created to treat the Marburg virus, but has shown promise in treating other types of viruses as well.

At this point, only time will tell how galidesivir fares. Even if the drug ends up receiving regulatory approval, it will still have to compete with the many other COVID-19 treatments in development. 

Promising non-COVID treatments

While it's easy to get focused on COVID-19 treatments, BioCryst has arguably a much more impressive lineup of non-COVID-related drugs. One such product is already on the market, even if it's not generating much cash for BioCryst at the moment.

Rapivab is an influenza treatment developed by BioCryst that received U.S. Food and Drug Administration (FDA) approval in 2014. Since then, some of the biggest buyers of the drug have been federal health authorities. The Centers for Disease Control bought $13.9 million worth of Rapivab in the fourth quarter of 2019 as part of a procurement contract with BioCryst. 

As for BioCryst's upcoming pipeline, there's quite a bit of anticipation surrounding berotralstat, which has finished its phase 3 trials and is currently awaiting regulatory approval. Berotralstat treats a rare type of swelling called hereditary angioedema, which affects about one in 50,000 people. These severe swelling attacks tend to affect the arms and legs but can also irritate the intestinal tract and the airways in the lungs.

BioCryst expects peak sales of about $500 million for berotralstat, which is a pretty big deal for a small-cap company whose market valuation is around $700 million. The FDA is expected to make a decision on berotralstat by Dec. 3 of this year.

Two scientists working at a lab with beakers and vials.

Image source: Getty Images.

Looking at the financials

As is to be expected for a small-cap biotech company, BioCryst has very little in the way of revenue. The company saw just $4.8 million in income for its first quarter, with most of that figure coming from various R&D and royalty revenue agreements. Considering that total expenses for the quarter came in at $45.8 million, it's not surprising that BioCryst's net losses were large, at $37.6 million.

All of this is par for the course for early-stage biotech companies. What's more important, however, is whether BioCryst has enough cash to finance its operations for the foreseeable future. In addition to the $114.6 million cash position BioCryst reported in its first quarter, the company raised $115 million through a stock offering in June. Now, with around $230 million in total cash, the company has about a year and a half's worth of financial breathing room based on its current rate of expenditure.

Is BioCryst a Buy?

While BioCryst has received a lot of attention as a potential player in the COVID-19 treatment market, there's a stronger case to be made for the company's other treatments.

BioCryst already has one drug that's received regulatory approval, proof that the company can successfully develop drug candidates to completion. While its first drug hasn't been a financial home run, there's a lot of potential surrounding its second major drug, berotralstat. If it ends up receiving regulatory approval later this year, berotralstat could be a major financial win.

Until that happens, however, there's still a lot of uncertainty surrounding this company. If you're comfortable with taking a high-risk, high-reward investment approach, buying a small number of shares could be a good idea right now. Just make sure to keep your initial position relatively small for the time being.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$14.16 (-0.63%) $0.09
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$64.83 (-1.80%) $-1.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.